Osteosarcoma
240
52
73
82
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
33 trials with published results (14%)
Research Maturity
82 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.7%
28 terminated out of 240 trials
74.5%
-12.0% vs benchmark
4%
9 trials in Phase 3/4
40%
33 of 82 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 82 completed trials
Clinical Trials (240)
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Agnostic Therapy in Rare Solid Tumors
Musculoskeletal Cancers Remote Monitoring and Care
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Regorafenib in Patients With Refractory Primary Bone Tumors
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Upfront Surgical Resection for Osteosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors